As more gene therapies outside the oncology and rare disease space come to the market, strategies for paying for these expensive treatments are set to evolve. Treatments with larger patient populations and wider usage are likely to come with lower prices than rare disease or oncology gene therapies, yet prices are likely to be relatively high compared with other new medicine because of the greater development costs associated with gene therapies, according to Paul Goudreau, executive director & head of Phase IV Solutions at the CRO Covance. Scrip looks at how stakeholders are considering how to move forward in terms of paying for expensive new therapies.